Navigation Links
NicOx Reports Results for the First Three Quarters of 2008
Date:10/22/2008

zer's decision not to launch a

phase 3 program.

Eric Castaldi, Chief Financial Officer at NicOx, said: "During the third quarter of 2008 we have achieved considerable success in the development of naproxcinod, while keeping the necessary control on expenses. We are very encouraged by the positive top-line results from the 302 phase 3 study, which comfortably met its efficacy endpoints and supported naproxcinod's non-detrimental effect on blood pressure, as well as by the good long term safety data observed in the 301 extension study.

We have also significantly advanced our pre-launch activities for naproxcinod, through the signature of an agreement for the manufacture of naproxcinod capsules for future commercialization, and are confident that the New Drug Application will be filed in mid 2009 as planned. We remain focused on the finalization of the clinical program for naproxcinod and look forward to the results of the 303 phase 3 study and the 111 and 112 Ambulatory Blood Pressure Monitoring studies in the coming months. As anticipated, our cash balance at the end of the third quarter is EUR124.8 million, which will enable us to fully finance the remaining clinical trials for naproxcinod and continue to advance the development of the other compounds in our portfolio."

Financial summary of the first nine months of 2008:

Revenues were EUR2.9 million for the nine months ended September 30, 2008, compared to EUR18.4 million during the same period in 2007. These revenues were due to the allocation of payments received from Pfizer Inc and Merck & Co., Inc. following the agreements signed with the two companies in the fields of ophthalmology and hypertension, respectively.

For the first nine months of 2008, operating expenses were EUR60.4 million, compared to EUR39.0 million for the corresponding period of 2007. As expected, the majority of these expenses were due to research and development costs related to naproxcinod, NicOx'
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
2. NicOx Announces Departure of Damian Marron for CEO Position
3. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
4. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
5. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
6. NicOx Opens U.S. Headquarters in New Jersey
7. Wyeth Reports Earnings Results for the 2008 Third Quarter and First Nine Months
8. Sigma-Aldrich (Nasdaq: SIAL) Reports 18.5% Gain in Q3 2008 Diluted EPS and Reaffirms Full Year 2008 Diluted EPS Forecast. Q3 2008 Sales Increase 7.4%. Buyback Authorization Increased by 10 Million Shares.
9. Amylin Pharmaceuticals Reports Third Quarter Financial Results
10. Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
11. Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Regis Technologies looks forward to ... Cancer Research (AACR) annual meeting. Regis will exhibit at ... Saturday, April 18, in Philadelphia and running through April ... of the oldest and largest organization focused on cancer ... and partners with survivors to promote awareness and research ...
(Date:4/16/2015)... , April 16, 2015  In recognition of World Hemophilia ... hemophilia advocacy groups to illuminate more than 15 prominent landmarks ... Boston,s Zakim Bridge and Prudential Tower, ... Orleans, Mercedes-Benz Superdome and Denver,s ... the evening of April 17, and coincide with hemophilia community ...
(Date:4/16/2015)... 16, 2015 ChemRar ... investment and R&D group, and Lancet, Russian ... development and commercialization of new medicines in ... intention to stimulate the innovative development of ... (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , ...
(Date:4/16/2015)... Avelas Biosciences, an in vivo ... today that it has initiated a Phase 1b study ... with primary, non-recurrent breast cancer undergoing surgery. In commencing ... of Steven Chen , M.D., as vice president ... escalation study will enroll up to 39 women with ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... 16, 2011  BioStorage Technologies, a global provider of comprehensive ... virtual sample intelligence and tracking for the bioscience industry, ... named "CFO of the Year" by the Indianapolis Business ... in the private companies category with $100 million or ...
... 15, 2011 Kevin W. Sharer, chairman and chief executive ... has announced his plan to retire from the Company at ... Amgen.  To facilitate an orderly transition process, Sharer will step ... chairman of the Company,s Board of Directors until December 31, ...
... WARREN, Mich., Dec. 15, 2011   Ecology Coatings, Inc. ... advanced coatings, today announced that it has developed bio-based ... Because these components are GRAS, they can be used ... and can be placed in direct contact with food ...
Cached Biology Technology:BioStorage Technologies' Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products 2
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces its biometric ... the products featured in 2015 "I Want That" International ... EST on the DIY Network.   DIY,s ... , site of the 2015 International CES for ...
(Date:3/18/2015)... 18, 2015 As mobile payments become ... smart wallets and apps continue to be introduced into the ... the mobile payment industry in focus today are:  NXT-ID, Inc. ... BABA ), Apple Inc. (NASDAQ: AAPL ... Inc. (NASDAQ: FB ) NXT-ID, Inc. ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... in on finding an effective bait to get ahead ... is now killing not only lodgepole pine forests, but ... Research Chair in Forest Entomology in the University of ... emitted by the pest in North America,s lodgepole and ...
... multi-model-based assessment of so-called Durban Platform scenarios, conducted by ... Institute for Climate Impact Research (PIK) and the Fondazione ... is the current negotiation track at the Warsaw climate ... by 2015 to come into effect in 2020. ...
... new research shows that the Plasmodium vivax ... in 2010, may be "rapidly evolving" to overcome the natural ... Africans, scientists reported today at the annual meeting of the ... In large swaths of sub-Saharan Africa, some 95 ...
Cached Biology News:Bait research focused on outsmarting destructive beetle 2Success of climate talks vital for 2°C target 2Success of climate talks vital for 2°C target 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: